Clinical trials: COVID-19 Convalescent Plasma Treatment
Hospitalized Children, Covid-19 Infection
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
This is a multicentered, open-label, randomized controlled Phase 2 trial to evaluate the safety and efficacy of providing human coronavirus-immune convalescent plasma as treatment for COVID-19 disease in hospitalized children in…
- Trial name
- CONCOR-KIDS (NCT04377568)
- Testing
- Convalescent plasma (CP)
- Where
- 13 sites in Canada
- Sponsor
- The Hospital for Sick Children
Covid19
Convalescent Plasma for Treatment of COVID-19
Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicate that it is safe for treatment of COVID-19.
- Trial name
- NCT04649879
- Testing
- SARS-CoV-2 convalescent plasma, Standard of care
- Where
- 3 sites in Sweden
- Volunteers
- 59 people
- Sponsor
- Joakim Dillner
Covid19
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
This study proposes to evaluate the therapeutic efficacy, immunologic effects and normalization of laboratory parameters for patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19) when administered one unit…
- Trial name
- NCT04513158
- Testing
- Convalescent Plasma
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Joseph M. Flynn, D.O., MPH
Covid19
Convalescent Plasma Treatment in COVID-19
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred initially in December 2019 in the city of Wuhan, Hubei province, China.
- Trial name
- COLLATE (NCT04476888)
- Testing
- Convalescent Plasma (CP), Drugs and supportive care
- Where
- Pakistan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
COVID
"NORPLASMA" Covid-19 Convalescent Plasma Treatment Monitoring Study
NORPLASMA COVID-19 includes both the production of convalescent plasma from approved blood donors who have recovered from covid-19 (coronavirus disease 2019), and clinical studies to evaluate efficacy and safety of the treatment…
- Trial name
- MONITOR (NCT04463823)
- Where
- 7 sites in Norway
- Volunteers
- 500 people
- Sponsor
- Oslo University Hospital
COVID-19
Convalescent Plasma Therapy - Zurich Protocol
This is an open-label, single-center, phase I study to assess the safety and efficacy of convalescent plasma therapy (CPT) obtained from donors who were tested positive for SARS-CoV-2 and fully recovered from the infection and…
- Trial name
- CPT-ZHP (NCT04869072)
- Testing
- Convalescent plasma
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Zurich
Covid19
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
This pilot, prospective study will assess the safety and efficacy of COVID-19 convalescent plasma versus standard care as treatment for severe and/or critical COVID-19 (as defined in the inclusion criteria) in adults 18 years of…
- Trial name
- NCT04554992
- Testing
- COVID 19 Convalescent Plasma
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- The Methodist Hospital Research Institute
COVID-19 Convalescent Plasma Treatment
Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients
Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more…
- Trial name
- Covid-IC (NCT05905380)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Corona Virus Infection
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions
This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either…
- Trial name
- NCT04462848
- Testing
- anti-SARS-CoV-2 human convalescent plasma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
COVID-19 Infection, Cancer Patients
COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)
COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the…
- Conditions
- COVID-19 Infection, Cancer Patients, General Population
- Trial name
- FALP-COVID (NCT04384588)
- Testing
- Convalescent Plasma from COVID-19 donors
- Where
- Chile
- Volunteers
- 100 people
- Sponsor
- Fundacion Arturo Lopez Perez
Convalescence, Corona Virus Infection
Convalescent Plasma Therapy in Patients With COVID-19
Scientists and medical workers all around the world were running out of time to manage COVID-19. Several studies have been done to understand the disease and ultimately to find possible treatment.
- Conditions
- Convalescence, Corona Virus Infection, Plaque
- Trial name
- NCT04407208
- Testing
- Convalescent plasma
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Biofarma
COVID-19, SARS-CoV 2
Convalescent Plasma for the Treatment of Patients With COVID-19
This expanded access program will provide access to COVID-19 convalescent plasma 150 or more individuals with moderate to severe or life-threatening manifestations of COVID-19, or documented to be at high risk of developing such…
- Trial name
- NCT04372368
- Testing
- COVID-19 Convalescent Plasma
- Where
- 6 sites in United States
- Sponsor
- University of Colorado, Denver
Covid19
Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma
The coronavirus disease 2019 (COVID-19) was classified as a pandemic by the World Health Organization (WHO) in March 2020. The SARS-COV-2 virus is easily transmissible and there is currently no approved treatment with effective…
- Trial name
- NCT04803370
- Testing
- Convalescent Plasma with antibody against SARS-CoV-2., Standard treatment for COVID-19
- Where
- Spain
- Volunteers
- 55 people
- Sponsor
- Hospital Son Llatzer
COVID 19
Anti COVID-19 Convalescent Plasma Therapy
Why is the research needed? The pandemic known as COVID-19 is now spreading across the world with currently (April 10, 2020) more than 1 115 530 active cases and 96 791 deaths.
- Trial name
- NCT04345679
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- Hungary
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orthosera Kft.
SARS Virus, SARS-CoV-2
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia
A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of…
- Conditions
- SARS Virus, SARS-CoV-2, COVID-19
- Trial name
- PLASM-AR (NCT04383535)
- Testing
- Convalescent SARS COVID-19 plasma
- Where
- Argentina
- Volunteers
- 333 people
- Sponsor
- Hospital Italiano de Buenos Aires
COVID-19
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
COVID-19 (Corona Virus Disease 2019) hospitalized patients evolution is marked by the risk of worsening of the respiratory system during the second week of the disease.
- Trial name
- PLASCOSSA (NCT04372979)
- Testing
- Transfusion of SARS-CoV-2 Convalescent Plasma., Transfusion of standard Plasma.
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
COVID-19
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
This is a Phase II study. This research study is being conducted to use convalescent donor plasma in seriously ill patients who have COVID-19.
- Trial name
- NCT04354831
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Medical College of Wisconsin
COVID-19
Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19
Research Question: Does convalescent plasma (CCP) collected from donors who have recovered from COVID-19 and who have a very high titre of anti-SARS-CoV-2 antibodies reduce the risk of hospitalisation (for COVID-19) or death in…
- Trial name
- COVIC-19 (NCT05271929)
- Testing
- Current standard of care and COVID-19 convalescent and vaccinated plasma, Current standard of care
- Where
- 14 sites in France, Germany and 2 more
- Volunteers
- 120 people
- Sponsor
- Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen
COVID-19
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program
This is an expanded access treatment protocol to treat up to 100 patients with severe or life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma.
- Trial name
- NCT04363034
- Testing
- Convalescent Plasma
- Sponsor
- University of Arkansas
Coronavirus Disease 2019 (COVID-19)
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04545047
- Testing
- COVID-19 convalescent plasma
- Where
- 2 sites in United States
- Volunteers
- 5,044 people
- Sponsor
- VA Office of Research and Development